What the FDA labels say about taking them together
Doxorubicin and trastuzumab
Doxorubicin's FDA label of May 5, 2026 names trastuzumab in its drug interactions section, and trastuzumab's label names doxorubicin too. The doxorubicin label: “… therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab.”
Check it at the source: the doxorubicin FDA label on DailyMed (effective May 5, 2026, Pfizer Laboratories Div Pfizer Inc); the trastuzumab FDA label on DailyMed (effective May 29, 2026, Genentech, Inc.).
What does the doxorubicin label say about trastuzumab?
Doxorubicin label, drug interactionsDo not administer doxorubicin hydrochloride in combination with trastuzumab due to increased risk of cardiac dysfunction
Doxorubicin label, warnings and precautionsThere is an additive or potentially synergistic increase in the risk of cardiomyopathy in patients who have received radiotherapy to the mediastinum or concomitant therapy with other known cardiotoxic agents, such as cyclophosphamide and trastuzumab.
Source: FDA drug label (Doxorubicin Hydrochloride), Pfizer Laboratories Div Pfizer Inc, effective May 5, 2026 (SPL set 1fd148fb-0fbc-4b6f-b790-23546fb46a71), via openFDA; the full label on DailyMed
What does the trastuzumab label say about doxorubicin?
Trastuzumab label, warnings and precautionsNSABP B31 & NCCTG N9831 Median follow-up duration for NSABP B31 & NCCTG N9831 combined was 8.3 years in the AC→paclitaxel+Herceptin arm.; AC Anthracycline (doxorubicin) and cyclophosphamide. →Paclitaxel+Herceptin; 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology.; 1.3% (21/1655)
Ogivri label (Mylan Institutional LLC, February 8, 2021), warnings and precautions1 & 2 Median follow-up duration for studies 1 and 2 combined was 8.3 years in the AC → TH arm.; AC Anthracycline (doxorubicin) and cyclophosphamide. → Paclitaxel + Trastuzumab; 3.2% (64/2000) Includes 1 patient with fatal cardiomyopathy and 1 patient with sudden death without documented etiology.; 1.3% (21/1655)
Source: FDA drug label (Kanjinti, BLA761073), Amgen, Inc, effective June 23, 2026 (SPL set 9a94f5b2-b84e-4987-8ea1-c4346db5a5fa), via openFDA
Source: FDA drug label (Herzuma, BLA761091), Cephalon, Inc., effective December 22, 2025 (SPL set ae71c003-883a-4cd8-ad50-e8cc9a54e971), via openFDA
Source: FDA drug label (Ogivri, BLA761074), Mylan Institutional LLC, effective February 8, 2021 (SPL set 6b7938e6-14c7-4a65-9605-967542ecfb8f), via openFDA
Source: FDA drug label (Herceptin), Genentech, Inc., effective May 29, 2026 (SPL set 492dbdb2-077e-4064-bff3-372d6af0a7a2), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Doxorubicin | Trastuzumab | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma, Breast cancer | Breast cancer |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | n/a | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once